Literature DB >> 6889513

Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography.

J Lankelma, P G Penders, J G McVie, A Leyva, W W Ten Bokkel-Huinink, M M de Planque, H M Pinedo.   

Abstract

In 9 patients with advanced malignant disease who received carminomycin (CMM) in an i.v. bolus injection (dose 18 mg/m2), curves of plasma concentrations of CMM and carminomycinol (CMMOH), a metabolite, versus time were constructed. For determination of plasma concentrations, high pressure liquid chromatography was used. For CMM and CMMOH the median areas under the curves (AUC's) were 31 (range 4-57) X 10(-8) mol/Ql/hr (measured over 24 hr) and 100 (range 309-158) X 10(-8) mol/l/hr (measured over 48 hr) respectively. From the data an accumulation of CMMOH in patients receiving treatments separated by brief intervals ban be predicted (half-life time of plasma disappearance for CMMOH was 2 days). Clinical toxicity was lowest in those 3 patients showing the lowest AUC for both CMM and CMMOH.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889513     DOI: 10.1016/0277-5379(82)90007-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  5 in total

Review 1.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 2.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

3.  Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).

Authors:  P Dodion; T A Davis; M Rozencweig; N Crespeigne; Y Kenis; N R Bachur
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

4.  Pharmacokinetics of 4'-epi-doxorubicin in man.

Authors:  H Weenen; J Lankelma; P G Penders; J G McVie; W W ten Bokkel Huinink; M M de Planque; H M Pinedo
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

5.  Phase II study of carminomycin in a human tumor cloning assay.

Authors:  M Rozencweig; C Sanders; W Rombaut; N Crespeigne; G Decoster; Y Kenis; J Klastersky
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.